Table 2.
Patient clinical and demographic characteristics.
| PD, n = 60 | iRBD, n = 60 | iRBD-POF, n = 23 | iRBD-AOF, n = 32 | |
|---|---|---|---|---|
| Mean/SD (range) or n (%) | Mean/SD (range) or n (%) | Mean/SD (range) or n (%) | Mean/SD (range) or n (%) | |
| Clinical characteristics | ||||
| Male gender | 60 (100%) | 60 (100%) | 23 (100%) | 32 (100%) |
| Age (years) | 61.8/11.6 (34−81) | 65.6/7.1 (46−81) | 63.7/8.5 (46−77) | 67.6/5.7 (57−81) |
| Symptom duration (years) | 1.1/1.5 (0.3−5.9) | 6.5/5.5 (1−28) | 5.8/4.0 (1−13) | 8.5/8.4 (1−39) |
| MoCA | 25.5/3.1 (17−30) | 24.1/2.7 (18−30) | 24.5/2.5 (20−29) | 23.8/3.0 (18−30) |
| SCOPA-AUT | 8.8/5.2 (0-23) | 12.4/7.6 (1-33) | 15.3/9.4 (1-33) | 11.0/5.6 (2-23) |
| UPSITa | 20.9/7.5 (2-35) | 22.1/7.9 (9-37) | 30.2/3.4 (26-37) | 16.3/4.5 (9-24) |
| MDS-UPDRS III total | 22.5/11.8 (10−63) | 6.8/6.2 (0−25) | 6.0/5.9 (0−22) | 7.3/6.4 (0−25) |
| MDS-UPDRS III speech item | 0.5/0.5 (0−2) | 0.1/0.3 (0−1) | 0.0/0.0 (0−0) | 0.1/0.3 (0−1) |
| MDS-UPDRS III tremor subscore | 6.3/4.0 (0−15) | 2.3/2.5 (0−11) | 2.3/3.0 (0−11) | 2.1/2.4 (0−9) |
| MDS-UPDRS III PIGD subscore | 2.5/1.5 (0−6) | 0.7/0.9 (0−4) | 0.5/0.7 (0−2) | 0.9/1.0 (0−4) |
| MDS-UPDRS III bradykinesia and rigidity subscore | 12.5/9.1 (4−42) | 0.6/0.8 (0−3) | 2.7/3.1 (0−11) | 3.7/4.4 (0−20) |
| iRBD presence | 17 (28%) | 60 (100%) | 23 (100%) | 32 (100%) |
| Brain imaging (DAT-SPECT) | ||||
| Caudate binding ratio | 2.8/0.6 (1.3−3.8) | 3.6/0.7 (2.3−5.4) | 3.8/0.7 (2.5−5.3) | 3.4/0.6 (2.3−5.4) |
| Putamen binding ratio | 1.5/0.4 (0.8−2.5) | 2.8/0.7 (1.3−4.5) | 3.1/0.6 (1.9−4.1) | 2.6/0.7 (1.3−4.5) |
| Abnormal DAT-SPECT | 60 (100%) | 16 (27%) | 3 (13%) | 12 (38%) |
PD Parkinson’s disease, iRBD isolated rapid eye movement sleep behaviour disorder, iRBD-POF iRBD patients with preserved olfactory function, iRBD-AOF iRBD patients with abnormal olfactory function, MDS-UPDRS Movement Disorder Society Unified Parkinson disease rating scale, PIGD Postural instability and gait difficulty, MoCA Montreal cognitive assessment, SCOPA-AUT Scales for Outcomes in Parkinson’s Disease - Autonomic Dysfunctionm, UPSIT University of Pennsylvania Smell Identification Test, DAT-SPECT dopamine transporter single-photon emission computed tomography, aUPSIT was not available in five subjects